Safety and Tolerability of Active Immunotherapy Targeting alpha-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Safety and Tolerability of Active Immunotherapy Targeting alpha-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
J Parkinsons Dis. 2021 May 27. doi: 10.3233/JPD-212594. Online ahead of print.ABSTRACTBACKGROUND: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson's disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation.OBJECTIVE: This phase 1 study characterized the safety and tolerability of PD03A in patients ... read more
Source: PubMedPublished on 2021-06-07By Werner Poewe